Wholesale
Athena

Aerami Therapeutics

Private Equity

Register Interest

The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are an accredited investor under the definition of that term in Rule 501(a) of Regulation D of the US Securities Act of 1933, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Transaction Size
USD 15,000,000.00
Share Price
USD 1,000.00
Minimum Investment
USD 50,000.00
Issue Type
Private Equity
Sector
Health Care

An opportunity exists to register interest for the purchase of Series A Preferred Stock (Shares) in Aerami Therapeutics Holdings, Inc.

The opportunity is open solely to investors who qualify as “accredited investors,” as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”). This private placement is exempt from registration under the Securities Act and applicable state securities laws.

Aerami is developing novel inhaled therapies for the treatment of chronic diseases. https://aerami.com/inhalation-technology/. Its platform is designed to overcome limitations of injectable and other inhaled formulation technologies for managing chronic diseases, and ultimately improve treatment efficacy and patient experience.

Aerami is advancing a diverse pipeline of inhaled therapies for the treatment of chronic diseases in the endocrinology, respiratory and cardiovascular space.

The initial focus was on diabetes. Areami developed a soft mist inhaled human insulin for patients with type 1 and 2 diabetes which has demonstrated a faster onset and similar profile to injectable insulin in clinical studies. In addition,it has formulated a pre-meal rapid acting Glucagon like Peptide Analog (GLP-1) to help patients with type 2 diabetes keep their postprandial hyperglycemia (hyperglycemia after meals) under control.

Aerami is now broadening its focus beyond diabetes to include additional chronic conditions that could potentially achieve better treatment efficiency from the patient friendly administration afforded by the AFINA Inhaler. Its pipeline therapies target hypoparathyroidism, osteoporosis and human growth hormone deficiency (HGH), which could benefit from the frequent pulsatile administration of inhaled parathyroid hormone and HGH.

For more information, click on the Register Interest button and you will be contacted by an advisor to the Issuer.

No items found.

Join our Issuer newsletter

Our quarterly Issuer newsletter is for partners, businesses and anyone interested in what we’re up to, platform updates and market commentary. To sign up to the Investor newsletter for marketplace offers click here.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.